Literature DB >> 15665597

Distribution and excretion of a phosphorothioate oligonucleotide in rats with experimentally induced renal injury.

Lilit Masarjian1, Ann de Peyster, Arthur A Levin, David K Monteith.   

Abstract

The effects of renal injury on the urinary excretion and tissue distribution of a 20-mer phosphorothioate oligonucleotide were investigated in male Sprague-Dawley rats. Renal injury was produced by treating the rats with either 5.0 mg/kg cisplatin or 2.5 mg/kg of a monoclonal antibody (mAb) directed toward Thy1.1. Controls received saline. Three days after cisplatin treatment or 2 days after anti- Thy1.1 treatment, the rats received 10 mg/kg ISIS 3521. Blood was collected at various times to assess the plasma concentrations of ISIS 3521, and rats were killed at various times from 6 to 48 hours after intravenous (i.v.) infusion of oligonucleotide to assess tissue concentrations by capillary gel electrophoresis (CGE). Cisplatin and anti-Thy1.1 antibody produced histologic and biochemical changes consistent with proximal tubular damage and glomerular damage, respectively. Urinary excretion of oligonucleotides was increased 2- to 4-fold of control; however, this amount accounted for only 1% to 2% of dose compared to 0.5% in controls. Proximal tubular damage reduced renal accumulations of ISIS 3521 and other oligonucleotide metabolites, but there were no obvious compensatory increases in concentrations in other organs except for a slight increase in spleen levels of total oligonucleotide. Glomerular damage was not associated with any change in oligonucleotide disposition. Immunohistochemical studies showed no evidence of alterations in the pattern of distribution within the injured kidney. The data suggest that acute renal dysfunction, either renal tubular or glomerular, does not markedly alter the urinary elimination and tissue deposition of a phosphorothioate oligonucleotide.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15665597     DOI: 10.1089/oli.2004.14.299

Source DB:  PubMed          Journal:  Oligonucleotides        ISSN: 1545-4576


  5 in total

1.  MicroRNA-21 promotes fibrosis of the kidney by silencing metabolic pathways.

Authors:  B Nelson Chau; Cuiyan Xin; Jochen Hartner; Shuyu Ren; Ana P Castano; Geoffrey Linn; Jian Li; Phong T Tran; Vivek Kaimal; Xinqiang Huang; Aaron N Chang; Shenyang Li; Aarti Kalra; Monica Grafals; Didier Portilla; Deidre A MacKenna; Stuart H Orkin; Jeremy S Duffield
Journal:  Sci Transl Med       Date:  2012-02-15       Impact factor: 17.956

2.  Anti-microRNA-21 oligonucleotides prevent Alport nephropathy progression by stimulating metabolic pathways.

Authors:  Ivan G Gomez; Deidre A MacKenna; Bryce G Johnson; Vivek Kaimal; Allie M Roach; Shuyu Ren; Naoki Nakagawa; Cuiyan Xin; Rick Newitt; Shweta Pandya; Tai-He Xia; Xueqing Liu; Dorin-Bogdan Borza; Monica Grafals; Stuart J Shankland; Jonathan Himmelfarb; Didier Portilla; Shiguang Liu; B Nelson Chau; Jeremy S Duffield
Journal:  J Clin Invest       Date:  2014-11-21       Impact factor: 14.808

3.  Toxicological and pharmacokinetic properties of chemically modified siRNAs targeting p53 RNA following intravenous administration.

Authors:  James D Thompson; Douglas J Kornbrust; Jeffrey W-D Foy; Elisabeth C R Solano; David J Schneider; Elena Feinstein; Bruce A Molitoris; Shai Erlich
Journal:  Nucleic Acid Ther       Date:  2012-08       Impact factor: 5.486

4.  siRNA targeted to p53 attenuates ischemic and cisplatin-induced acute kidney injury.

Authors:  Bruce A Molitoris; Pierre C Dagher; Ruben M Sandoval; Silvia B Campos; Hagit Ashush; Eduard Fridman; Anat Brafman; Alexander Faerman; Simon J Atkinson; James D Thompson; Hagar Kalinski; Rami Skaliter; Shai Erlich; Elena Feinstein
Journal:  J Am Soc Nephrol       Date:  2009-05-21       Impact factor: 10.121

5.  Discovery and preclinical evaluation of anti-miR-17 oligonucleotide RGLS4326 for the treatment of polycystic kidney disease.

Authors:  Edmund C Lee; Tania Valencia; Charles Allerson; Annelie Schairer; Andrea Flaten; Matanel Yheskel; Kara Kersjes; Jian Li; Sole Gatto; Mandeep Takhar; Steven Lockton; Adam Pavlicek; Michael Kim; Tiffany Chu; Randy Soriano; Scott Davis; John R Androsavich; Salma Sarwary; Tate Owen; Julia Kaplan; Kai Liu; Graham Jang; Steven Neben; Philip Bentley; Timothy Wright; Vishal Patel
Journal:  Nat Commun       Date:  2019-09-12       Impact factor: 14.919

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.